循环肿瘤细胞在晚期乳腺癌中的临床意义和治疗应用。

Clinical Relevance and Therapeutic Application of CTCs in Advanced Breast Cancer.

机构信息

Medical Oncology Department, Complejo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, A Coruña, Spain.

Medical Oncology Department, HM La Esperanza Centro Integral Oncológico Clara Campal de Galicia, Santiago de Compostela, A Coruña, Spain.

出版信息

Adv Exp Med Biol. 2020;1220:147-164. doi: 10.1007/978-3-030-35805-1_10.

DOI:10.1007/978-3-030-35805-1_10

PMID:32304085

Abstract

Precision medicine through liquid biopsy represents an emerging approach in the management of cancer. The CTC count in blood samples from patients with advanced breast cancer is a powerful prognostic factor for both progression free and overall survival. Moreover, high levels of CTCs at any time during the treatment can reliably predict progression before imaging studies and/or tumor markers. Furthermore, there are works on the molecular characterization of the CTCs and their potential ability to guide the treatment in a dynamic way. However, their role remains controversial. Detection and enumeration of CTCs is variable among different tumors and is subjected to biases related mainly to their methodology, which is not completely standardized. In addition, they must demonstrate their clinical value to guide the treatment and a translation on patient's survival.

摘要

液体活检指导下的精准医疗是癌症治疗领域的新兴方法。晚期乳腺癌患者血液样本中的循环肿瘤细胞（CTC）计数是无进展生存期和总生存期的有力预后因素。此外，治疗过程中任何时间的 CTC 水平升高都可以在影像学研究和/或肿瘤标志物之前可靠地预测疾病进展。此外，已有研究对 CTC 的分子特征及其潜在的动态治疗指导能力进行了探索。然而，其作用仍存在争议。不同肿瘤之间 CTC 的检测和计数存在差异，主要受到其检测方法的影响，这些方法尚未完全标准化。此外，它们必须证明其在指导治疗和提高患者生存方面的临床价值。